Search results
Horizon Therapeutics is a biotechnology company that is driven to deliver breakthrough medicines to patients because we understand the challenges they face.
- 116.30Add to watchlist0.00 (0.00%)At close: Tue. May 28, 2024 4:00 PM EDT · Delayed Quote (USD) · Market closed
- Open116.34High116.30Low116.30
- Mkt CapN/AP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close116.3052 Wk. Low116.3052 Wk. High116.30
Related stocks
Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. [4]
Oct 6, 2023 · Strengthening of Amgen 's leading inflammation portfolio by adding first-in-class, early-in-lifecycle medicines such as TEPEZZA® (teprotumumab-trbw), KRYSTEXXA® (pegloticase) and UPLIZNA® (inebilizumab-cdon), which treat rare inflammatory diseases.
Oct 6, 2023 · Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain ...
Jun 22, 2023 · DUBLIN, June 22, 2023--Horizon Therapeutics has announced positive topline results from the OPTIC-J clinical trial of TEPEZZA in Japan for active Thyroid Eye Disease (TED).
Dec 12, 2022 · Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion.
Jul 21, 2023 · DUBLIN, July 21, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically ...
Apr 14, 2023 · TEPEZZA is the first and only medicine approved by the FDA for the treatment of TED – a serious, progressive, debilitating and potentially vision-threatening rare autoimmune disease. 1 ...
Feb 1, 2021 · Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under.
Mar 7, 2022 · Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) granted priority review of the supplemental B.
